Abstract
Conventional 1-methyl-2-oxobarbiturates and 1-methyl-2-thiobarbituates which are employed as anesthetics tend to accumulate in the body due to their slow rate of metabolism. As a result, the use of these compounds is restricted to either as an induction agent for anesthesia, subsequently maintained by volatile anesthetics or to a short surgical procedures only. In order to overcome the limitations of application of barbiturates as general anesthetics, avoiding the use of volatile agents, an attempt was made to the structural modifications of barbiturates molecules as intravenous anesthetics. In view of this contexts, it was conceived that, by incorporating metabolically labile ester functions in one or both of the side chain of barbiturates ring system, it could be achieved. Since this procedure could diminish the likelihood of barbiturates to be accumulated in the body, it might be possible to get safer barbiturate intravenous anesthetics. This classification arose from the observation that whilst the biological properties of some drugs are extremely sensitive to minor changes in stereo-chemical feature, electron distribution and substituent, there are many other drugs which exhibit similar patterns of biological behavior, despite a wide diversity in their chemical configurations. This has been appeared to be the case with the barbiturate esters as discussed in this communication.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
